Yazar "Bahcivan, Emre" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Cardiac safety of gamithromycin in ewes
    (2016) Corum, Orhan; Dik, Burak; Bahcivan, Emre; Eser, Hatice; Er, Ayse; Yazar, Enver
    Amaç: Bir makrolid antibiyotik olan gamitromisin sığırlarda pasteurellosis tedavisinde önerilmekle birlikte koyunlarda etiket dışı olarak kullanılmaktadır. Makrolid antibiyotiklerin kardiyotoksik etkileri bilinmektedir, ancak gamitromisinin koyunlarda kardiyak güvenilirliği ile ilgili bilgi bulunmamaktadır. Araştırmanın öncelikli amacı koyunlarda gamitromisinin kardiyak güvenilirliğini belirlemektir. Bunun yanı sıra karaciğer ve böbrek fonksiyonlarına ve hemogram parametrelerine etkisini tespit etmektir.Gereç ve Yöntem: Araştırmada 10 adet koyuna gamitromisin (6 mg/kg, SC) tek doz olarak uygulandı. Kan örnekleri uygulamadan önce (0. gün, kontrol) ve sonraki 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8 ve 9. günlerde alındı. Spesifik kalp hasar belirteçleri olan serum kreatin kinaz-MB kütle ve troponin I düzeyleri, karaciğer ile böbrek hasar belirteçleri ve hemogram parametreleri ölçüldü. Bulgular: Araştırmada troponin I düzeyinde birinci gün istatistiki olmayan yükselmeler belirlenirken, kreatin kinaz-MB kütle düzeyinde değişimler belirlenmedi. Total bilirubin, total protein, kreatinin ve akyuvar düzeyinde referans değerler arasında istatistiki değişimler belirlendi (P0.05).
  • Küçük Resim Yok
    Öğe
    Corynebacterium cutis Lysate Treatment Can Increase the Efficacies of PPR Vaccine
    (MARY ANN LIEBERT, INC, 2016) Dik, Burak; Dik, Irmak; Bahcivan, Emre; Avci, Oguzhan
    This study aimed to evaluate the effects of Peste des petits ruminants (PPR) vaccine on cytokine and antibody levels in sheep when administered alone or in combination with Corynebacterium cutis lysate (CCL). The PPR vaccine group received a single subcutaneous axillary injection of the PPR vaccine (1mL containing tissue culture infectious dose (TCID)(50) attenuated live PPRV, n=6) and the combination treatment (1mL CCL and 1mL PPR vaccine, n=6) groups received a single subcutaneous axillary injection of both CCL and PPR vaccine. Blood samples were collected from sheep before the treatment and at different points after treatment (1, 3, 7, 14, 21, and 28 days). Plasma and serum samples were evaluated for antibody percentage, levels of cytokines IL-6, IL-10, IFN-, IL-4, IL-12, and IL-18, oxidative stress marker Thiobarbituric acid reactive substances, and hematological and biochemical parameters. Maximum protective antibody levels reach 3-4 weeks after vaccine administration. The combination treatment resulted in significant changes in IFN-, IL-4, IL-12, and IL-18 cytokine levels. These changes were not evident when only the PPR vaccine was administered and antibody percentage against PPRV was short term in PPR vaccine group. In conclusion, combined usage of the PPR vaccine with CCL resulted in a heightened cytokine response, leading to improved antibody level against PPR virus. Repeated CCL treatments can lead to earlier vaccine potency, provide protective efficacy for a longer time, and increase passive immunity.
  • Küçük Resim Yok
    Öğe
    Pharmacokinetics of ceftriaxone following single ascending intravenous doses in sheep
    (ELSEVIER SCIENCE BV, 2018) Corum, Duygu Durna; Corum, Orhan; Altan, Feray; Faki, Hatice Eser; Bahcivan, Emre; Er, Ayse; Uney, Kamil
    The objective of this study was to evaluate the pharmacokinetics of CTX following intravenous administration of ascending doses in sheep. In this study, six clinically healthy Akkaraman sheep (2.4 +/- 0.4 years and 50 +/- 3 kg of body weight) were used. CTX was administered intravenously to each sheep at 20, 40, and 80 mg/kg doses in a crossover design with a 15-day washout period. Plasma concentrations of CTX were measured using the high-performance liquid chromatography-UV method. Pharmacokinetic parameters were calculated by non-compartmental analysis. CTX was well tolerated following administration at 20, 40, and 80 mg/kg doses. The elimination half-life following administration of 40 and 80 mg/kg doses were significantly longer than that of 20 mg/kg dose (P < 0.05). The volume of distribution at steady state was similar among the groups (P > 0.05). When compared to 20 mg/kg, dose-normalized AUC(0-infinity) at the 80 mg/kg dose significantly increased (P < 0.05). The relation between dose and AUC(0-infinity) was linear. Our study showed that CTX can be used at 12-h intervals for 20, 40, and 80 mg/kg doses to maintain T > minimum inhibitory concentration (MIC) of > 40% for the treatment of infections caused by bacteria with MIC values <= 2, <= 4, and <= 16 mu g/mL, respectively. This information may be helpful in adjusting the dosage regimen, but there is a need for future work.